

Daniela Rottoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10115659/publications.pdf>

Version: 2024-02-01

41
papers

4,512
citations

147801

31
h-index

276875

41
g-index

41
all docs

41
docs citations

41
times ranked

5446
citing authors

#	ARTICLE	IF	CITATIONS
1	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1794-1804.	6.1	690
2	Disruption of the Ang II type 1 receptor promotes longevity in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 524-530.	8.2	434
3	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. <i>Stem Cells</i> , 2008, 26, 2075-2082.	3.2	351
4	Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. <i>Journal of Clinical Investigation</i> , 2015, 125, 715-726.	8.2	335
5	Insulin-Like Growth Factor-1 Sustains Stem Cell-Mediated Renal Repair. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2921-2928.	6.1	294
6	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. <i>Journal of Immunology</i> , 2011, 187, 172-180.	0.8	220
7	Add-On Anti-TGF- β 2 Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1816-1824.	6.1	177
8	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2898-2908.	6.1	156
9	Transforming Growth Factor- β 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins. <i>American Journal of Pathology</i> , 2002, 161, 2179-2193.	3.8	138
10	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. <i>Nature Communications</i> , 2017, 8, 983.	12.8	124
11	Protein Overload Induces Fractalkine Upregulation in Proximal Tubular Cells through Nuclear Factor- κ B and p38 Mitogen-Activated Protein Kinase-Dependent Pathways. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2436-2446.	6.1	118
12	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1448-F1456.	2.7	114
13	Proximal tubular cells promote fibrogenesis by TGF- β 1-mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002, 61, 2066-2077.	5.2	109
14	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002, 61, 1635-1645.	5.2	103
15	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 804-813.	6.1	99
16	Transcriptional Regulation of Nephritin Gene by Peroxisome Proliferator-Activated Receptor- γ 3 Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1624-1632.	6.1	76
17	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. <i>PLoS ONE</i> , 2013, 8, e70775.	2.5	75
18	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. <i>Kidney International</i> , 2006, 70, 97-103.	5.2	71

#	ARTICLE	IF	CITATIONS
19	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. <i>American Journal of Pathology</i> , 2007, 170, 1165-1177.	3.8	70
20	Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1158-1167.	6.1	63
21	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009, 76, 960-967.	5.2	56
22	Distinct cardiac and renal effects of ET _A receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F1114-F1123.	2.7	56
23	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , 2017, 60, 1114-1125.	6.3	54
24	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. <i>Kidney International</i> , 2004, 66, 1959-1965.	5.2	52
25	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1786-1798.	6.1	52
26	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001, 60, 653-663.	5.2	49
27	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1629-1637.	6.7	46
28	Beneficial Effect of TGF β 2 Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. <i>Nephron Experimental Nephrology</i> , 2006, 104, e158-e168.	2.2	43
29	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. <i>Nephron</i> , 2015, 129, 52-61.	1.8	43
30	Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin. <i>Journal of Immunology</i> , 2008, 181, 1460-1469.	0.8	37
31	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016, 132, 59-69.	1.8	36
32	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. <i>Kidney International</i> , 2019, 96, 906-917.	5.2	31
33	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. <i>Stem Cell Research and Therapy</i> , 2018, 9, 220.	5.5	26
34	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. <i>EBioMedicine</i> , 2015, 2, 456-466.	6.1	24
35	COVID-19 Attacks the Kidney: Ultrastructural Evidence for the Presence of Virus in the Glomerular Epithelium. <i>Nephron</i> , 2020, 144, 341-342.	1.8	24
36	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF/caveolin-1/PV β signaling pathway. <i>Journal of Pathology</i> , 2022, 256, 468-479.	4.5	21

#	ARTICLE	IF	CITATIONS
37	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. <i>American Journal of Pathology</i> , 2017, 187, 2441-2450.	3.8	20
38	Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. <i>Journal of Hypertension</i> , 2018, 36, 1129-1146.	0.5	14
39	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021, 145, 428-444.	1.8	5
40	Histological Examination of the Diabetic Kidney. <i>Methods in Molecular Biology</i> , 2020, 2067, 63-87.	0.9	4
41	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. <i>Journal of Immunology</i> , 2022, 208, 1772-1781.	0.8	2